Neutrophil-to-Lymphocyte Ratio Is Associated With the Proportion of Poorly Differentiated Components in Papillary Thyroid Carcinoma

J Surg Res. 2023 Jul:287:47-54. doi: 10.1016/j.jss.2023.01.010. Epub 2023 Mar 1.

Abstract

Introduction: Diagnosis of poorly differentiated thyroid cancer (PDTC) requires ≥ 50% of poorly differentiated components (PDC) in Japan. However, the optimal cutoff percentage of PDC for PDTC diagnosis remains controversial. Although high neutrophil-to-lymphocyte ratio (NLR) correlates with the aggressiveness of papillary thyroid cancer (PTC), whether NLR is associated with the proportion of PDC in PTC remains unstudied.

Materials and methods: Patients with the pure PTC (n = 664), PTC with < 50% PDC (n = 19), or PTC with ≥ 50% PDC (n = 26) who underwent surgery were retrospectively analyzed. Twelve-year disease-specific survival and preoperative NLR were compared among these groups.

Results: Twenty seven patients died from thyroid cancer. The PTC with ≥ 50% PDC group (80.7%) showed significantly worse 12-year disease-specific survival than the pure PTC group (97.2%) (P < 0.001); however, the < 50% PDC group (94.7%) did not (P = 0.91). The PTC with ≥ 50% PDC group had a significantly higher NLR than the pure PTC (P < 0.001) and the PTC with < 50% PDC groups (P < 0.001), whereas there was no significant difference in the NLR between the pure PTC and the PTC with < 50% PDC groups (P = 0.48).

Conclusions: PTC with ≥ 50% PDC is more aggressive than either pure PTC or PTC with < 50% PDC, and NLR potentially reflects the PDC proportion. These results support the validity of 50% PDC as a cut-off for PDTC diagnosis and indicate the utility of NLR as a biomarker for PDC proportion.

Keywords: Neutrophil-to-lymphocyte ratio; Poorly differentiated component; Poorly differentiated thyroid cancer.

MeSH terms

  • Adenocarcinoma* / pathology
  • Carcinoma, Papillary* / pathology
  • Carcinoma, Papillary* / surgery
  • Humans
  • Lymphocytes
  • Neutrophils / pathology
  • Prognosis
  • Retrospective Studies
  • Thyroid Cancer, Papillary / diagnosis
  • Thyroid Cancer, Papillary / pathology
  • Thyroid Cancer, Papillary / surgery
  • Thyroid Neoplasms* / diagnosis
  • Thyroid Neoplasms* / pathology
  • Thyroid Neoplasms* / surgery

Substances

  • prolinedithiocarbamate